Collplant Biotechnologies Ltd
NASDAQ:CLGN
Relative Value
The Relative Value of one CLGN stock under the Base Case scenario is 69.14 USD. Compared to the current market price of 5.88 USD, Collplant Biotechnologies Ltd is Undervalued by 91%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
CLGN Competitors Multiples
Collplant Biotechnologies Ltd Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
IL |
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
67.3m USD | 6.1 | -9.6 | -7.3 | -6.1 | ||
US |
Abbvie Inc
NYSE:ABBV
|
286.9B USD | 5.3 | 59.5 | 12.9 | 19.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
161B USD | 5.5 | 42.8 | 18.2 | 30 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
105.9B USD | 10.7 | 29.2 | 23.5 | 24.6 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.1B USD | 8.1 | 27.5 | 22.2 | 24.7 | ||
AU |
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.9B USD | 3 | 169.3 | 6.8 | 8.9 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
45.7B USD | 8.9 | -7.7 | -8.3 | -7.3 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.6B USD | 3.3 | 27.1 | 13.9 | 17.3 | ||
KR |
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.2 | 46 | 63.3 |